SparingVision Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
39
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$40.3M
- Investors
-
17
SparingVision General Information
Description
Developer of a medical therapy designed to treat retinal diseases and vision loss disorders. The company's offerings include a drug candidate to treat retinitis pigmentosa, the most frequent inherited retinal degeneration that can progress to blindness and affects many patients worldwide, intending to preserve and restoring visual function, enabling biotechnology and healthcare organizations to create treatments for inherited and degenerative retinal conditions.
Contact Information
Website
www.sparingvision.comCorporate Office
- 5/7 Avenue Percier
- CS40230
- 75008 Paris
- France
Corporate Office
- 5/7 Avenue Percier
- CS40230
- 75008 Paris
- France
SparingVision Timeline
SparingVision Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC | 30-Jun-2025 | $40.3M | Completed | Generating Revenue | ||
| 11. Accelerator/Incubator | 01-Jan-2024 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 01-Oct-2023 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 8. Later Stage VC (Series B) | 12-Sep-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 13-Oct-2021 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A) | 21-Oct-2020 | Completed | Generating Revenue | |||
| 5. Grant | 01-Oct-2019 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 09-Jul-2019 | $2.82M | $20M | Completed | Generating Revenue | |
| 3. Grant | 01-Jan-2017 | $316K | $17.1M | Completed | Startup |
SparingVision Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class B Shares | ||||||||
| Class B Shares | ||||||||
| A2 Shares | ||||||||
| A2 Shares | ||||||||
| Series A | 61,426 | $1.151041 | $140.54 | $140.54 | 1x | $140.54 | 3.89% | |
| A Shares | 80,000 | $1.151041 | $115.1 | $115.1 | 1x | $115.1 | 5.07% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
SparingVision Comparisons
Industry
Financing
Details
SparingVision Competitors (1)
One of SparingVision’s competitors is jCyte, a Venture Capital-Backed company based in Newport Beach, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| jCyte | Venture Capital-Backed | Newport Beach, CA |
SparingVision Patents
SparingVision Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260193723-A1 | Methods of detecting replication competent aav | Pending | 18-Oct-2024 | ||
| WO-2026083130-A1 | Methods of detecting replication competent aav | Pending | 18-Oct-2024 | ||
| AU-2023362592-A1 | Compositions and methods for treating retinal degenerative disorders | Pending | 20-Oct-2022 | ||
| EP-4605537-A1 | Compositions and methods for treating retinal degenerative disorders | Pending | 20-Oct-2022 | ||
| WO-2024084075-A1 | Compositions and methods for treating retinal degenerative disorders | Inactive | 20-Oct-2022 | A61K48/005 |
SparingVision Signals
SparingVision Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| La French Tech | Accelerator/Incubator | |||
| Inserm Transfert | VC-Backed Company | Minority | ||
| Retinal Degeneration Fund | Not-For-Profit Venture Capital | Minority | ||
| Intellia Therapeutics | Corporation | Minority | ||
| 4BIO Capital | Venture Capital | Minority |
SparingVision Investments & Acquisitions (2)
SparingVision’s most recent deal was a Early Stage VC with Tenpoint Therapeutics for . The deal was made on 12-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tenpoint Therapeutics | 12-Jul-2023 | Early Stage VC | Drug Discovery | ||
| Gamut Therapeutics | 20-Apr-2021 | Merger/Acquisition | Drug Discovery |
SparingVision FAQs
-
When was SparingVision founded?
SparingVision was founded in 2016.
-
Where is SparingVision headquartered?
SparingVision is headquartered in Paris, France.
-
What is the size of SparingVision?
SparingVision has 39 total employees.
-
What industry is SparingVision in?
SparingVision’s primary industry is Drug Discovery.
-
Is SparingVision a private or public company?
SparingVision is a Private company.
-
What is the current valuation of SparingVision?
The current valuation of SparingVision is .
-
What is SparingVision’s current revenue?
The current revenue for SparingVision is .
-
How much funding has SparingVision raised over time?
SparingVision has raised $205M.
-
Who are SparingVision’s investors?
La French Tech, Inserm Transfert, Retinal Degeneration Fund, Intellia Therapeutics, and 4BIO Capital are 5 of 17 investors who have invested in SparingVision.
-
Who are SparingVision’s competitors?
jCyte is a competitor of SparingVision.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process